caa a22 4500 467921776 CHVBK 20180406152919.0 cr unu---uuuuu 170328e20060201xx s 000 0 ger 10.1007/s10309-006-0155-7 doi (NATIONALLICENCE)springer-10.1007/s10309-006-0155-7 Generika in der Epilepsietherapie [Elektronische Daten] Was ist zu beachten? [Günter Krämer, Dieter Dennig, Dieter Schmidt, Bettina Schmitz, Hermann Stefan, Bernhard Steinhoff, Ulrich Stephani, Stefan Stodieck] Generics in antiepileptic drug therapy: What has to be considered? The approval of generic preparations for the first two of the so-called new antiepileptic drugs (AEDs; gabapentin and lamotrigine) is reason for the German Society for Epileptology (Deutsche Gesellschaft für Epileptologie; DGfE) to comment from a medical point of view on the usage of generics as AEDs once more in addition to an earlier paper regarding the "aut idem” problem. Generic preparations can in general be used without problems for the initial treatment or for alternative therapy with AEDs if a switch is considered anyhow due to insufficient efficacy or tolerability. However, patients with freedom from seizures and side effects should not be switched unfoundedly from a branded to a generic preparation, between different generics or from an generic to a branded preparation. Therefore, the DGfE recommends correspondent statements on the prescription (crossing of the "aut idem” field or inscription/stamp "no substitution”) as well as informing the patients or their relatives. The potential risks related to switches between different AED preparations with the same active ingredient have to be reasonably low in view of the physician and the patient. If a switch is considered, the patients have to be informed about the risks of seizure recurrence or reduced tolerability and asked for their consent. Otherwise the physician is liable to damage claims in case of occurring problems. Steinkopff-Verlag, 2006 Generic preparations nationallicence antiepileptic drugs nationallicence aut idem nationallicence Generika nationallicence Antiepileptika nationallicence Aut idem nationallicence Krämer Günter Medizinischer Direktor, Schweizerisches Epilepsie-Zentrum, Bleulerstrasse 60, 8008, Zürich, Switzerland aut Dennig Dieter Neurologische Praxis, Stuttgart aut Schmidt Dieter Forschungsgruppe Epilepsie, Berlin aut Schmitz Bettina Neurologische Klinik und Poliklinik der Charité, Berlin aut Stefan Hermann Neurologische Universitätsklinik, Erlangen aut Steinhoff Bernhard Klinik für Erwachsene Epilepsiezentrum Kork, Kehl-Kork aut Stephani Ulrich Klinik für Neuropädiatrie der Universitätskinderklinik, Kiel aut Stodieck Stefan Epilepsiezentrum Hamburg, Hamburg aut Zeitschrift für Epileptologie Steinkopff-Verlag 19/1(2006-02-01), 1-5 1617-6782 19:1<1 2006 19 10309 https://doi.org/10.1007/s10309-006-0155-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10309-006-0155-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Krämer Günter Medizinischer Direktor, Schweizerisches Epilepsie-Zentrum, Bleulerstrasse 60, 8008, Zürich, Switzerland aut NATIONALLICENCE 700 1- Dennig Dieter Neurologische Praxis, Stuttgart aut NATIONALLICENCE 700 1- Schmidt Dieter Forschungsgruppe Epilepsie, Berlin aut NATIONALLICENCE 700 1- Schmitz Bettina Neurologische Klinik und Poliklinik der Charité, Berlin aut NATIONALLICENCE 700 1- Stefan Hermann Neurologische Universitätsklinik, Erlangen aut NATIONALLICENCE 700 1- Steinhoff Bernhard Klinik für Erwachsene Epilepsiezentrum Kork, Kehl-Kork aut NATIONALLICENCE 700 1- Stephani Ulrich Klinik für Neuropädiatrie der Universitätskinderklinik, Kiel aut NATIONALLICENCE 700 1- Stodieck Stefan Epilepsiezentrum Hamburg, Hamburg aut NATIONALLICENCE 773 0- Zeitschrift für Epileptologie Steinkopff-Verlag 19/1(2006-02-01), 1-5 1617-6782 19:1<1 2006 19 10309 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer